Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Global Protein Assays Market, by Product Type (Reagents and Kits, Instruments), by Technology Type (Absorbance-based Protein Assays, Colorimetric Protein Assays, Fluorescence-based Protein Assays), by Assay Type (Dye Binding Assays, Copper-Ion based Assays, Test Strip based Assays and Other Protein Assays) and by End User (Pharmaceutical and Biotechnology Companies, Clinical Laboratories, Hospitals and Academic Research Institutes) was valued at US$ 1,503.7 million in 2016 and is projected to exhibit a CAGR of 7.6% over the forecast period (2017-2025), as highlighted in a new report published by Coherent Market Insights.
Protein quantification is a process in protein extraction in biochemistry and molecular biology labs that involves protein extraction, analysis, or labeling. Quantification of protein is required for protein sample and analysis by electrophoresis or chromatography or any other immunochemical techniques. Commonly used protein assays are Bradford, Lowry, BCA, and UV spectroscopic protein assays. In April 2017, Millipore Sigma launched a new Single Molecule Counting Platform, SMCxPROTM, which is based on the principle of immunoassay and it enables precise and sensitive detection over conventional methods. Increasing investments of pharmaceutical companies in protein assays is leading to development of various drugs. Protein assays initiatives have led to new discoveries and development of treatments tailored for specific characteristics such as genetic makeup or genetic profile of an individual tumor that helps to offer relatively better and effective treatment methods. In 2015, According to a publication by Pharmaceuticals Research and Manufacturers of America (PhRMA) — a trade group representing companies in the pharmaceutical industry in the U.S.— the member organizations (pharmaceutical companies) of PhRMA invested around US$ 58.8 billion on R&D, accounting for the largest of all the biopharmaceutical R&D spending in the U.S, in 2015.
Browse 29 Market Data Tables and 33 Figures spread through 180 Pages and in-depth TOC on "" Protein Assays Market, by Product Type (Reagents and Kits, Instruments), by Technology Type (Absorbance based Protein Assays, Colorimetric Protein Assays, Fluorescence based Protein Assays), by Assay Type (Dye Binding Assays, Copper-Ion based Assays, Test Strip based Assays and Other Protein Assays), by End User (Pharmaceutical and Biotechnology Companies, Clinical Laboratories, Hospitals and Academic Research Institutes) and by Region - Global Forecast to 2025""
To know the latest trends and insights related to protein assays market, click the link below:
https://www.coherentmarketinsights.com/market-insight/protein-assays-market-1087
Asia Pacific market is expected to witness highest growth in the global protein assays market over the forecast period, owing to rising application of protein content determination in pharmacy and biotechnology. Increasing private-public partnership for genetic analysis has aided in the market growth. Rising biotechnology and life sciences sector in this region as well as increasing focus on research and development by the top market players is another factor for growth of the market. For instance, in January, 2016, Thermo Fisher Scientific Inc. acquired Affymetrix to strengthen its position in biosciences and genetic analysis as well as extend geographic reach of Affymetrix's products by leveraging Thermo Fisher's market presence and infrastructure in Asia Pacific, particularly China.
Various new biomarker identification systems and emerging new uses for protein assays provided opportunities to the players in the global protein assay market. For instance, in June 2017, Gyros Protein Technologies AB launched a new version of its anti-drug antibody (ADA) solution for the immunogenicity segment. Gyrolab ADA solution enables to automatically run drug-tolerant ADA assays in a time efficient way reducing hands-on time, using small volumes of patient samples and reagents, and reducing run-times.
Manufacturers are likely to focus on launching systems, which are expected to help understand protein structures and functions, with tools to characterize post-translational modifications, localization, and expression control including epigenetic mechanisms. In June 2015, Thermo Fisher Scientific Inc. introduced Orbitrap Fusion Lumos Tribrid mass spectrometer and in 2017, it launched Integrated Ultraviolet Photo separation (UVPD) that enables specialists to perform substantial and little atom structure assurance on a Lorentz focus (LC) time scale; and new advanced peak determination (APD) calculation that is intended to enhance execution of most proteomic work processes with high peptide and protein ID rates.
Key Takeaways of the Protein Assays Market:
The global protein assays market is expected to exhibit a CAGR of 7.6% over the forecast period (2017-2025). This is attributed to increasing collaborations among pharmaceutical companies, academic researchers, regulators, and government organizations across various regions.
Among product type, reagents and kits segment is expected to account for the largest share in the global protein assay market over the forecast period. This is attributed to quick and ready-to-use modifications and the requirement of repeat purchase of reagents.
Among technology types, absorbance-based segment is expected to be largest contributor in terms of revenue to the global market over the forecast period, and this is primarily attributed to expanding effectiveness and accuracy of absorbance-based proteins
Some of the major players involved in global protein assays market are Thermo Fisher Scientific Inc., GE Healthcare, Merck KGaA, Bio-Rad Laboratories, Inc., Lonza, Abcam plc, PerkinElmer Inc., Bio-Techne, BioVision Inc., Cell Signaling Technology, Inc., and Geno Technology Inc.